Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
Laura L. Michel, Alexandra von Au, Athanasios Mavratzas, et al.
Targeted Oncology (2020) Vol. 15, Iss. 4, pp. 415-428
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Exosomes and breast cancer drug resistance
Xingli Dong, Xupeng Bai, Jie Ni, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 148
Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs
André E. Nel, Kuo‐Ching Mei, Yu‐Pei Liao, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5184-5232
Open Access | Times Cited: 45
Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer
Neelum Aziz Yousafzai, Lamyae El Khalki, Wei Wang, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 883-883
Open Access | Times Cited: 7
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
Adviti Naik, Julie Decock
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 45
Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
Huey‐Jen Lin, Yingguang Liu, Denene Lofland, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 285-285
Open Access | Times Cited: 22
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
Kamal S. Saini, Kevin Punie, Chris Twelves, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 7, pp. 945-962
Open Access | Times Cited: 32
Current treatment landscape and emerging therapies for metastatic triple-negative breast cancer
Jennifer Potash, Rachelle Laliberte, P. J. Silvėrman, et al.
The American Journal of Managed Care (2021) Vol. 27, Iss. Suppl 5, pp. S87-S96
Open Access | Times Cited: 28
CD169+ Macrophages in Primary Breast Tumors Associate with Tertiary Lymphoid Structures, Tregs and a Worse Prognosis for Patients with Advanced Breast Cancer
Oscar Briem, Eva Källberg, Siker Kimbung, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1262-1262
Open Access | Times Cited: 12
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Cirino Botta, Cristina Pérez, Marta Larráyoz, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Research progress of exosomes in drug resistance of breast cancer
Lihui Liu, Daqing Jiang, Shi Bai, et al.
Frontiers in Bioengineering and Biotechnology (2024) Vol. 11
Open Access | Times Cited: 4
Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma
Huey‐Jen Lin, Yingguang Liu, Kailey Caroland, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3507-3507
Open Access | Times Cited: 6
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
Daniele Marinelli, Marco Mazzotta, Laura Pizzuti, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2497-2497
Open Access | Times Cited: 17
Induction of Redox-Mediated Cell Death in ER-Positive and ER-Negative Breast Cancer Cells by a Copper(II)-Phenolate Complex: An In Vitro and In Silico Study
Vaiyapuri Subbarayan Periasamy, Anvarbatcha Riyasdeen, Venugopal Rajendiran, et al.
Molecules (2020) Vol. 25, Iss. 19, pp. 4504-4504
Open Access | Times Cited: 17
Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
Xingfa Huo, Guoshuang Shen, Zhen Liu, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 168, pp. 103530-103530
Closed Access | Times Cited: 15
PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
Joydeep Ghosh, Meheli Chatterjee, Sandip Ganguly, et al.
ecancermedicalscience (2021) Vol. 15
Open Access | Times Cited: 13
Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis
Xueyan Liang, Xiaoyu Chen, Huijuan Li, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 4
PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability
Jiaojiao Yu, Yujin Xiang, Yuzhen Gao, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4378-4395
Open Access | Times Cited: 1
ITIH5-Derived Polypeptides Covering the VIT Domain Suppress the Growth of Human Cancer Cells In Vitro
Michael Rose, Sebastian Huth, Marc Wiesehöfer, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 488-488
Open Access | Times Cited: 6
Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation
Qiheng Gou, Zijian Liu, Yuxin Xie, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6
MPA/DMBA-driven mammary carcinomas
Aitziber Buqué, María Pérez-Lanzón, Giulia Petroni, et al.
Methods in cell biology (2020), pp. 1-19
Closed Access | Times Cited: 7
Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
Yunhai Li, Lei Xing, Fan Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 7
The nature of triple-negative breast cancer classification and antitumoral strategies
Songmi Kim, Dong Hee Kim, Wooseok Lee, et al.
Genomics & Informatics (2020) Vol. 18, Iss. 4, pp. e35-e35
Open Access | Times Cited: 5
PARPi, immunothérapies et anticorps monoclonaux conjugués dans les cancers du sein triple-négatifs
Florence Dalenc, Victor Sarradin, Vincent Nicolaï, et al.
Bulletin du Cancer (2021) Vol. 108, Iss. 1, pp. 67-79
Closed Access | Times Cited: 4
Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment
Lingpeng Tang, Dandan Wang, Ting Hu, et al.
Cancer Drug Resistance (2024)
Open Access
Reawakening the master switches in triple-negative breast cancer: A strategic blueprint for confronting metastasis and chemoresistance via microRNA-200/205: A systematic review
Armia Ahmadi-Hadad, Paula Catarina Carvalho de Queiroz, Francesco Schettini, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104516-104516
Open Access
Page 1 - Next Page

Scroll to top